| 26th week of 2013 patent applcation highlights part 53 |
| Patent application number | Title | Published |
|---|
| 20130165375 | TREATMENT OF DEPRESSIVE DISORDERS - The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds to treat depressive disorders. | 2013-06-27 |
| 20130165376 | Heparin Binding Epidermal Growth Factor (HB-EGF) for Use in Methods of Treating and Preventing Intestinal Injury Related to Hemorrhagic Shock and Resuscitation - The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS/R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration of intestinal blood flow and methods of preserving and increasing intestinal blood flow by administering HB-EGF to a human subject. In addition, the methods of the invention should improve the clinical outcome of human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation. | 2013-06-27 |
| 20130165377 | PREVENTION OF MOLECULAR WEIGHT REDUCTION OF THE POLYMER, IMPURITY FORMATION AND GELLING IN POLYMER COMPOSITIONS - Polymer and drug containing compositions and method of preparing such compositions are disclosed. The dispersed phase formulation has a polymer, a pharmaceutically or biologically active agent and a small fraction of low pKa acid additive. Stable, filter sterilizable, non-gelling solutions containing GnRH analogues at least at levels typically used in sustained release formulations and a method of increasing solubility of a high level of a GnRH analogue or a freeze-dried antgonist of GnRH in a polymer containing solution are also disclosed. The amount of the acid additive in the polymer solution is such that it is sufficient to increase the solubility of the high level of the GnRH analogue in the polymer solution without affecting the release characteristics of the microspheres prepared therefrom. | 2013-06-27 |
| 20130165378 | METHOD OF TREATING HUMAN GROWTH HORMONE MEDIATED CONDITION - A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations. | 2013-06-27 |
| 20130165379 | Formulations of Exendins and Exendin Agonist Analogs - Provided herein are formulations containing exendins, exendin, agonists and/or exendin analogs and methods of using the exendins, exendin agonists and/or exendin analogs and formulations thereof to treat glucagonoma and necrolytic migratory erythema, or to suppress glucagon secretion. | 2013-06-27 |
| 20130165380 | Administration of an antagonist of a5 1 for anti-angiogenesis and cancer treatment - The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an a5β1 antagonist with an a2β1 antagonist to a subject. The methods are for use in inhibiting, preventing, or reversing angiogenesis, as well as in treating cancer. In some embodiments, the compositions and methods include a combined administration of VLO4 and VP12 (ECL12). | 2013-06-27 |
| 20130165381 | LIPIDS, LIPID COMPLEXES AND USE THEREOF - The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), | 2013-06-27 |
| 20130165382 | CROSSLINKING OF PROTEINS AND OTHER ENTITIES VIA CONJUGATES OF ALPHA-HALOACETOPHENONES, BENZYL HALIDES, QUINONES, AND THEIR DERIVATIVES - The present invention relates to the formation of conjugates (e.g., protein-protein dimers) using a-halo-acetophenones, benzylic halides, quinones, and related compounds as a conjugating system. The invention also features compositions that include the conjugates described herein, as well as uses of these conjugates in methods of medical treatment. | 2013-06-27 |
| 20130165383 | APO-2 LIGAND/TRAIL VARIANTS AND USES THEREOF - The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided. | 2013-06-27 |
| 20130165384 | Decellularized small particle tissue - A process for producing a decellularized small particle tissue which involves selecting an appropriate tissue starting material from which a decellularized small particle tissue is desired to be prepared, treating the tissue with a decellularizing agent at an acid pH to remove at least a portion of the cellular material therefrom and to yield a product comprising a liquid component and a solid component, subjecting the liquid component and the solid component to a plurality of filters, F | 2013-06-27 |
| 20130165385 | NEUROGENIN - The invention relates to novel neurogenin proteins, nucleic acids and antibodies. | 2013-06-27 |
| 20130165386 | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSIS INDUCING ACTIVITY ON CELLS - Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs). | 2013-06-27 |
| 20130165387 | LOW FREQUENCY GLATIRAMER ACETATE THERAPY - A method of alleviating a symptom of relapsing-remitting multiple sclerosis in a human patient suffering from relapsing-remitting multiple sclerosis or a patient who has experienced a first clinical episode and is determined to be at high risk of developing clinically definite multiple sclerosis comprising administering to the human patient three subcutaneous injections of a therapeutically effective dose of glatiramer acetate over a period of seven days with at least one day between every subcutaneous injection so as to thereby alleviate the symptom of the patient. | 2013-06-27 |
| 20130165388 | Method of Producing a Paralytic Peptide - The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species | 2013-06-27 |
| 20130165389 | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN-DRUG CONJUGATES, XTEN-DRUG CONJUGATES AND METHODS OF MAKING AND USING SAME - The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions. | 2013-06-27 |
| 20130165390 | BORONATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF - The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases. | 2013-06-27 |
| 20130165391 | B2-GLYCOPROTEIN I PEPTIDE INHIBITORS - Therapeutic peptides (and peptoids) for preventing or inhibiting tissue damage associated with ischemia and/or reperfusion are provided, along with peptides (and peptoids) for preventing or inhibiting cancerous tissue growth. The peptides are derived from β2-glycoprotein I. Pharmaceutical and veterinary compositions comprising the peptides are also provided. Methods of using the peptides to prevent or inhibit tissue damage associated with ischemia and/or reperfusion and/or to prevent or inhibit tissue damage or the growth of cancerous tissue are also provided. | 2013-06-27 |
| 20130165392 | HEPATOCYTE GROWTH FACTOR MIMICS AS THERAPEUTIC AGENTS - Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, neurodegenerative disease, diabetes and metabolic syndrome, cancer, and defective wound healing. | 2013-06-27 |
| 20130165393 | PHOSPHOLIPID AND PROTEIN TABLETS - A new method for krill meal production has been developed using a two step cooking process. In the first step the proteins and phospholipids are removed from the krill and precipitated as a coagulum. In the second stage the krill without phospholipids are cooked. Following this, residual fat and astaxanthin are removed from the krill using mechanical separation methods. A novel krill meal product with superior nutritional and technical properties is prepared. | 2013-06-27 |
| 20130165394 | AMINO ACID COMPOSITION FOR IMPROVING GLUCOSE TOLERANCE - Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes. | 2013-06-27 |
| 20130165395 | METHODS OF TREATING DIABETES - Solid forms of anhydrous (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol are disclosed, in addition to methods of their use in the treatment of various diseases and disorders. | 2013-06-27 |
| 20130165396 | Apple Skin Extracts for Treating Cardiovascular Disease - Pharmaceutical and nutraceutical compositions and methods for treating cardiovascular disease, comprising apple skin extracts which can reduce cholesterol levels and inhibit low density lipoprotein (LDL) oxidation in a subject, are provided. | 2013-06-27 |
| 20130165397 | TREATMENT OF BACTERIAL INFECTIOUS DISEASES - The present invention relates to a novel pharmacological treatment of bacterial infectious diseases in humans. Specifically the invention relates to the use of apramycin of formula (I) or apramycin derivatives to treat bacterial infectious diseases in humans. It is demonstrated that apramycin surprisingly does not have the expected high level of toxicity observed with related aminoglycoside antibiotics but actually is even significantly less toxic than compounds already used in human medicine such as gentamicin. | 2013-06-27 |
| 20130165398 | CONCENTRATION-ENHANCING DRINK - A concentration-enhancing drink contains, in each case independently of one another, per liter: 1 mg to 10 g, preferably 1 to 1000 mg, still more preferably 10 to 500 mg, in particular 50 to 300 mg, of epigallocatechin gallate; 1 to 500 mg, preferably 10 to 100 mg, in particular 20 to 80 mg, of nicotinamide ribose; and/or 0.05 to 10 g, preferably 0.1 to 5 g, in particular 0.5 to 3 g of tryptophan. | 2013-06-27 |
| 20130165399 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, CONTAINING ADENOSINE N1-OXIDE AS AN EFFECTIVE INGREDIENT - The present invention has an object to provide an effective and safe therapeutic agent for inflammatory diseases such as sepsis, hepatitis, and inflammatory bowel disease, and solves the above object by providing a therapeutic agent for inflammatory diseases containing adenosine N1-oxide or a derivative thereof as an effective ingredient. | 2013-06-27 |
| 20130165400 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. | 2013-06-27 |
| 20130165401 | NUCLEOSIDE PHOSPHORAMIDATES - Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals. | 2013-06-27 |
| 20130165402 | SURGICAL GEL SYSTEM - A surgical gel system for coating and adhering to a wound area to control bleeding whilst supporting wound healing comprises polyanhydroglucuronic acid or a biocompatible salt in an amount of from 1% to 15% by weight and pectin in an amount of in an amount of from 0.1% to 9% by weight. The gel system may be used for stopping bleeding during or after sinus surgery, for stopping bleeding in ear nose and throat procedures, for stopping bleeding in gynecological procedures, or for stopping bleeding in internal organ procedures. | 2013-06-27 |
| 20130165403 | Process for Manufacturing Partially Cross-Linked Alginate Solution - Described is a microfluidic process for manufacturing partially cross-linked alginate solution, wherein the alginate solution is a homogenous liquid which exhibits an elastic response (G′) which is equal to or greater than its viscous response (G″). In particular, the process may comprise microfluidic mixing of sodium alginate and calcium gluconate solutions to provide an injectable partially cross-linked alginate solution. | 2013-06-27 |
| 20130165404 | HYBRID COOPERATIVE COMPLEXES OF HYALURONIC ACID - Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food. | 2013-06-27 |
| 20130165405 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 2013-06-27 |
| 20130165406 | POLYMORPHS OF 2'-O-FUCOSYLLACTOSE AND PRODUCING THEREOF - The present invention relates to novel polymorphs of the trisaccharide 2′-O-fucosyllactose (2-FL) of formula (1), methods for producing said polymorphs and their use in pharmaceutical or nutritional compositions. | 2013-06-27 |
| 20130165407 | Prebiotic Formulations and Methods of Use - The invention provides methods and compositions for treating symptoms associated with lactose intolerance and for overall improvement in gastrointestinal health. Described herein are methods and compositions for improving overall gastrointestinal health or for decreasing symptoms of lactose intolerance by administering to subject in need thereof a prebiotic composition, optionally in combination with effective amount of a probiotic microbe or microbes. | 2013-06-27 |
| 20130165408 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILESY - A method for treatment or prevention epilepsy comprising administering a phenyl carbamate compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of epilepsy is provided. | 2013-06-27 |
| 20130165409 | PHENYL CARBAMATE COMPOUNDS FOR USE IN ALLEVIATING OR TREATING PAIN - A phenyl carbamate compound; a composition for treating and/or alleviating pain containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or alleviating pain comprising administering the phenyl carbamate compound or a pharmaceutically acceptable salt thereof to a patient in need of pain treatment; and a use of the phenyl carbamate compound or a pharmaceutically acceptable salt thereof in treating and/or alleviating pain, are provided. | 2013-06-27 |
| 20130165410 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING STROKE - A phenyl carbamate compound; a composition for treating and/or preventing stroke containing the phenyl carbamate compound or a pharmaceutically acceptable salt thereof as an active ingredient; a method of treating and/or preventing stroke comprising administering the phenyl carbamate compound or a pharmaceutically acceptable salt thereof to a patient in need of stroke treatment; and a use of the phenyl carbamate compound or a pharmaceutically acceptable salt thereof in treating and/or preventing stroke, are provided. | 2013-06-27 |
| 20130165411 | TRICYCLIC BORON COMPOUNDS FOR ANTIMICROBIAL THERAPY - Provided herein are antimicrobial tricyclic boron compounds of the following formula I: | 2013-06-27 |
| 20130165412 | CANNABINOID RECEPTOR MODULATORS - The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activities of both the CB1 receptor and the CB2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pain, for example bone and joint pain, muscle pain, dental pain, migraine and other headache pain, inflammatory pain, neuropathic pain, pain that occurs as an adverse effect of therapeutics and pain associated with osteoarthritis; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; CNS inflammation; atherosclerosis; undesired immune cell activity and inflammation; age-related macular degeneration; cough; leukemia; lymphoma; CNS tumors; prostate cancer; Alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis, and Parkinson's disease. | 2013-06-27 |
| 20130165413 | PROCESS FOR THE PREPARATION OF TENOFOVIR - The present invention provides a process for the preparation of tenofovir. The present invention also provides a process for the preparation of tenofovir disoproxil or a salt thereof and its pharmaceutical composition using the tenofovir of the present invention. | 2013-06-27 |
| 20130165414 | PHOSPHATE ESTERS OF NORIBOGAINE - Disclosed herein are phosphate esters of noribogaine and dihydronoribogaine, and esters and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the methods of their use, including in the treatment of addiction and/or pain. | 2013-06-27 |
| 20130165415 | CHEMICAL COMPOUNDS - The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. | 2013-06-27 |
| 20130165416 | COMPOUNDS AND USES THEREOF IN MODULATING LEVELS OF VARIOUS AMYLOID BETA PEPTIDE ALLOFORMS - The invention provides a novel compound having a structure corresponding to Formula (I): | 2013-06-27 |
| 20130165417 | METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED DISORDERS - The invention relates to methods of treating cardiovascular and cardiopulmonary diseases and associated conditions, including hypertension. The invention further relates to pharmaceutical compositions for treating cardiovascular and cardiopulmonary diseases, especially hypertension, and lung injury. | 2013-06-27 |
| 20130165418 | OPIOID AGONIST/OPIOID ANTAGONIST/ACETAMINOPHEN COMBINATIONS - The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome). | 2013-06-27 |
| 20130165419 | COMBINATION ANTI-INFLAMMATORY OPHTHALMIC COMPOSITIONS - Compositions and systems for topical ophthalmic application, which include an aqueous mixture of steroidal and non-steroidal anti-inflammatory agents in a flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye. | 2013-06-27 |
| 20130165420 | SILICONE-BASED COMPOSITION FOR SKIN TREATMENT - The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients. | 2013-06-27 |
| 20130165421 | 4-[17BETA-METHOXY-17ALPHA-METHOXYMETHYL-3-OXOESTRA-4,9-DIEN-11-BETA-YL]BEN- ZALDEHYDE (E)-OXIME (ASOPRISNIL) - The present invention relates to a method for the reliable and reproducible preparation of 4-[17β-methoxy-17α-methoxymethyl-3-oxoestra-4,9-dien-11β-yl]benzaldehyde (E)-oxime (asoprisnil) on the pilot and manufacturing scale. Asoprisnil, which is prepared by this method, is distinguished by a very good physical stability and is therefore particularly suitable for the manufacture of solid pharmaceutical forms (tablets, coated tablets, etc.). | 2013-06-27 |
| 20130165422 | HEXAFLUOROISOPROPYL CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The disclosure relates to hexafluoroisopropyl carbamate derivatives of general formula (I): | 2013-06-27 |
| 20130165423 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS - Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer. | 2013-06-27 |
| 20130165424 | DISPIROPYRROLIDINE DERIVATIVES - A compound that inhibits interaction between murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity is provided. The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity, wherein R | 2013-06-27 |
| 20130165425 | SULFATE ESTERS OF NORIBOGAINE - Disclosed herein are sulfate esters of noribogaine or 9,17 dihydronoribogaine, and pharmaceutically acceptable salts of each thereof, pharmaceutical compositions comprising such compounds, and methods of their use, including in treating addiction and/or pain. | 2013-06-27 |
| 20130165426 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS - Disclosed is a compound of Formula I or a salt thereof, in which X, X1, X2, R1, R2, and R3 are described herein. Also disclosed are pharmaceutical compositions and methods of using the compounds of Formula I to treat disorders mediated by melanocortin-4 receptors. | 2013-06-27 |
| 20130165427 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WARFARE AGENT-INDUCED INJURIES - Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein. | 2013-06-27 |
| 20130165428 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS - The present invention relates to substituted xanthines of general formula | 2013-06-27 |
| 20130165429 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously; may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients; and may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, other active ingredients, and DMSO or Sterile Water for Irrigation. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels. | 2013-06-27 |
| 20130165430 | COMPOSITION AND METHOD FOR COMPOUNDED THERAPY - The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. For instance, the transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine base cream to which is added a fine powder of one or more ground up medications to form a compounded medication. The compounded medication in powder form may be generated from grinding up tablets of NSAIDs, anticonvulsants, nerve depressants, antidepressants, muscle relaxants, NMDA receptor antagonists, opiate or opioid agonists, and/or other agents. The compounded medication in powder form may include meloxicam, lamotrigine, topiramate, and/or other active ingredients. In another aspect, the present embodiments relate to methods of compounding medications and transdermal creams or gels. | 2013-06-27 |
| 20130165431 | INHIBITORS OF SYK AND JAK PROTEIN KINASES - The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma. | 2013-06-27 |
| 20130165432 | Dual Modulators of 5HT2A and D3 Receptors - The present invention relates to compounds of the formula (I) | 2013-06-27 |
| 20130165433 | Novel Use - The present invention is directed to compounds for use in the treatment or prevention of influenza virus infection. | 2013-06-27 |
| 20130165434 | COMPOSITION FOR CONTROLLING HARMFUL ARTHROPODS AND METHOD FOR CONTROLLING HARMFUL ARTHROPODS - A harmful arthropod control composition comprising flonicamid, one or more Delphacidae control compounds selected from Group (A), and one or more rice blast disease control compounds selected from Group (B): | 2013-06-27 |
| 20130165435 | TOCOTRIENOL DERIVATIVES AND ASSOCIATED METHODS - Compositions of matter including (R)-2,5,6,8-tetramethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine and (R)-2,6,8-trimethyl-8-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl)-1,2,3,8,9,10-hexahydrochromeno[5,6-e][1,3]oxazine are disclosed herein. Further disclosed are methods of preparation of such compounds and the use of such compounds as anticancer agents. | 2013-06-27 |
| 20130165436 | Dihydro-Benzo-Oxazine and Dihydro-Pyrido-Oxazine Derivatives - The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, | 2013-06-27 |
| 20130165437 | NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS. - A compound according to Formula Ia: | 2013-06-27 |
| 20130165438 | PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS - The present invention provides a piperidine compound represented by Formula (I) | 2013-06-27 |
| 20130165439 | CHEMICAL COMPOUNDS - The present invention encompasses compounds of general formula (I) | 2013-06-27 |
| 20130165440 | JAK1 Inhibitors - JAK1 inhibitors of structural formula (I), wherein Ar | 2013-06-27 |
| 20130165441 | Novel Polymorphs and Salts - The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity. | 2013-06-27 |
| 20130165442 | Modulators of ATP-Binding Cassette Transporters - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators. | 2013-06-27 |
| 20130165443 | BIPHENYL AND PHENYL-PYRIDINE AMIDES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds of the formula I: | 2013-06-27 |
| 20130165444 | Piperidine Derivatives - Piperidine derivatives of which the following is exemplary | 2013-06-27 |
| 20130165445 | Aurora Kinase Modulators and Method of Use - The present invention relates to chemical compounds having a general formula I | 2013-06-27 |
| 20130165446 | BENZO-OR PYRIDO-IMIDAZOLE DERIVATIVE - The present invention addresses the problem of finding a compound having both PPAR activation activity and angiotensin receptor antagonistic activity. The present invention is a benzo- or pyrido-imidazole derivative represented by general formula (I), a pharmaceutically acceptable salt thereof, or a ester or amide thereof (where A is biphenyl methyl-imidazolyl, biphenyl methyl-benzimidazolyl, or the like, B is divalent benzimidazolyl or the like, C is carboxyl or the like, E is divalent phenyl, naphthyl, or the like, G is a dangling bond, oxygen, or the like, Q is oxygen or sulfur, n is an integer from 1 to 6, p is an integer from 1 to 6, V is a dangling bond, oxygen, or the like, and R is hydrogen, alkyl, or the like). | 2013-06-27 |
| 20130165447 | Inhibitors of PDE10 - PDE10 inhibitors having the general formula (I) | 2013-06-27 |
| 20130165448 | AILDENAFIL CITRATE CRYSTAL FORM O, PREPARATION METHOD AND USE THEREOF - The invention provides a 1-[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d] pyridine-5-group)-4-ethoxy-benzenesulfonyl]-cis-3,5-dimethylpiperazine citrate or an Aildenafil citrate crystal form O and a preparation method thereof. And the invention also provides pharmaceutical compositions containing the Aildenafil citrate crystal form O and the use thereof in preparing drugs for treating Male Erectile Dysfunction (ED). The above crystal form O can be prepared through the steps of: dissolving a raw material, namely, the Aildenafil citrate in a mixture of distilled water and tetrahydrofuran, stirring, heating, filtering, stirring a filtrate, cooling, insulating heat, crystallizing, filtering and the like. The crystal form O can be adopted to prepare drugs with pharmaceutically acceptable excipients, so as to treat the male sexual dysfunction diseases. | 2013-06-27 |
| 20130165449 | Compounds and Method for Treatment of Cancer - The present invention is directed to methods of use of a compound of Formula I: | 2013-06-27 |
| 20130165450 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors - This invention relates to certain thiazole carboxamide derivatives of Formula (I) as inhibitors of 3-phosphoinositide-dependent protein kinase (PDK-1). The compounds can be useful in inhibiting the proliferation of cancer cells, and other aberrant conditions where the PDK-1 signaling pathway is overstimulated. | 2013-06-27 |
| 20130165451 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain compounds, or pharmaceutically acceptable salts, solvates, clathrates, or prodrugs thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2013-06-27 |
| 20130165452 | Substituted Heteroaryls - The present invention provides Formula (1A) compounds | 2013-06-27 |
| 20130165453 | THERAPEUTIC EFFECTS OF BRYOSTATINS, BRYOLOGS, AND OTHER RELATED SUBSTANCES ON ISCHEMIA/STROKE-INDUCED MEMORY IMPAIRMENT AND BRAIN INJURY - The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke. | 2013-06-27 |
| 20130165454 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WAREFARE AGENT-INDUCED INJURIES - Compounds and compositions for treating injuries caused by exposure to chemical warfare agents are described herein. | 2013-06-27 |
| 20130165455 | TLR AGONISTS - The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore. | 2013-06-27 |
| 20130165456 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof. | 2013-06-27 |
| 20130165457 | INHIBITORS OF E1 ACTIVATING ENZYMES - This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia. | 2013-06-27 |
| 20130165458 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS - A compound for treating protein kinase-related disease or disorder having a structure of formula (A): | 2013-06-27 |
| 20130165459 | PHARMACEUTICAL COMPOSITION AND DOSAGE FORMS OF ELINOGREL AND METHODS OF USE THEREOF - The present invention is concerned with a solid delivery form of elinogrel for the treatment of thrombosis which is notable for its multi-pH dissolution, immediate release and improved pharmacokinetic properties and stability in storage. The delivery and dosage form is a solid, oral formulation comprising: a) at least about 15% by weight elinogrel or a pharmaceutically acceptable salt thereof relative to the total weight of the overall pharmaceutical composition, and b) at least one pharmaceutically acceptable carrier. A further aspect of the present invention concerns the preparation and use of such a formulation. | 2013-06-27 |
| 20130165460 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 2013-06-27 |
| 20130165461 | METHODS OF TREATING HEART FAILURE - Methods of treating heart failure by administration of beneficial agents to the heart. | 2013-06-27 |
| 20130165462 | HETEROARYL COMPOUNDS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2013-06-27 |
| 20130165463 | INHIBITION OF FOCAL ADHESION KINASE FOR CONTROL OF SCAR TISSUE FORMATION - The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) activity or expression. Blockade of FAK is sufficient to prevent mechanical and inflammatory stimuli from activating MCP-1 pathways. In addition to these chemokine-mediated mechanisms, inhibition of FAK may control fibrosis by blocking fibroblast collagen production. Pharmacologic blockade of FAK significantly reduces scar formation in vivo. | 2013-06-27 |
| 20130165464 | HETEROARYLS AND USES THEREOF - This invention provides compounds of formula IB: | 2013-06-27 |
| 20130165465 | Crystalline Forms of 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyr- idin-3-yl-pyrimidin-2-ylamino)-benzamide - Crystalline forms of 4-methyl-N-3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes. | 2013-06-27 |
| 20130165466 | POLYMER CONJUGATES OF OPIOID ANTAGONISTS - The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention. | 2013-06-27 |
| 20130165467 | MANUFACTURING OF ACTIVE-FREE GRANULES AND TABLETS COMPRISING THE SAME - The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings. | 2013-06-27 |
| 20130165468 | TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY - A method of treating peripheral neuropathic pain in humans resulting from a peripheral nerve injury and for treating muscle spasm in humans resulting from a peripheral nerve injury comprises applying a therapeutically effective amount of a drug selected from the group consisting of a dopamine agonist, a skeletal muscle relaxant, and a combination thereof topically to the site of the injury. | 2013-06-27 |
| 20130165469 | NOVEL NEUROMODULATORY COMPOUNDS - Provided herein are novel neuromodulatory compounds and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine and Parkinson's disease, using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT | 2013-06-27 |
| 20130165470 | Methods for Detecting and Treating Rhinovirus Infection - The invention provides a method for evaluating the activity of an agent for treating rhinovirus infection or a symptom thereof, a method of detecting or monitoring rhinovirus infection, and a method of treating rhinovirus infection or a symptom thereof. Various embodiments comprise measuring expression of (i) one or more genes selected from the group consisting of CRY2, B3GAT3, C10ORF95, and BATF3, and (ii) one or more genes selected from the group consisting of RNFT2, BTG4, PSD3, CAPN9, SULT1E1, HEY1, LRRC36, RAB3B, ALDH3B1, FAM134B, FAS, PLSCR1, CLEC2B, HAS2, MX1, SP110, GBP1, IFIT3, IFIT1, CXCL9, CXCL10, and CXCL11, from at least one biological sample to produce a gene expression profile, and comparing the gene expression profile to a reference gene expression profile. Systems, computer readable media, compositions, and methods for maintaining or improving respiratory health also are provided. | 2013-06-27 |
| 20130165471 | 2-SUBSTITUTED-THIENOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS - Disclosed herein are 2-substituted-thienoquinolones and related compounds and their pharmaceutically acceptable salts useful as antiviral agents and having the general formula | 2013-06-27 |
| 20130165472 | HETEROARYLS AND USES THEREOF - This invention provides compounds of formula IA: | 2013-06-27 |
| 20130165473 | Azaquinolinone Derivatives and Uses Thereof - The present invention provides compounds and methods for treating or preventing the development of a disease, disorder, or condition in a subject or patient. | 2013-06-27 |
| 20130165474 | COMPOUNDS THAT INHIBIT TAU PHOSPHORYLATION - The present invention provides methods and compositions for enhancing working memory impaired in a tau pathological condition associated with AD or Down's syndrome. | 2013-06-27 |
